VivoSim Labs, Inc. (LON:0R02)
3.174
+0.065 (2.09%)
At close: Mar 20, 2025
VivoSim Labs Employees
As of March 31, 2025, VivoSim Labs had 13 total employees, including 5 full-time and 8 part-time employees. The number of employees decreased by 7 or -35.00% compared to the previous year.
Employees
13
Change (1Y)
-7
Growth (1Y)
-35.00%
Revenue / Employee
7.97K GBP
Profits / Employee
-111.56K GBP
Market Cap
7.32M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 13 | -7 | -35.00% |
Mar 31, 2024 | 20 | -4 | -16.67% |
Mar 31, 2023 | 24 | 6 | 33.33% |
Mar 31, 2022 | 18 | 9 | 100.00% |
Mar 31, 2021 | 9 | 3 | 50.00% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Genus | 3,500 |
VivoSim Labs News
- 5 months ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire
- 5 months ago - VivoSim to Carry Forward Organovo 3D Bioprinting - GlobeNewsWire
- 6 months ago - Organovo reports $11.3M cash balance in FY24 - Seeking Alpha
- 6 months ago - Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements - GlobeNewsWire
- 6 months ago - Organovo gets upfront payments following sale of its FXR Program to Lilly - Seeking Alpha
- 6 months ago - Organovo Provides Business Update - GlobeNewsWire
- 6 months ago - Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company - GlobeNewsWire
- 6 months ago - Organovo announces reverse stock split; shares fall - Seeking Alpha